This case report describes the first known instance of semaglutide-induced acute interstitial nephritis in a patient without pre-existing chronic kidney disease. The authors suggest that as GLP-1 receptor agonist prescriptions increase, particularly in CKD patients, regular clinical follow-up and careful kidney function monitoring during dose escalation should be considered. Here, GLP1R is linked to chronic kidney disease.